BusinessAxsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business UpdateBy Nasdaq OMXMay 8, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric AssociationBy Nasdaq OMXMay 3, 2018, 11:02 AM UTC
BusinessAxsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking CessationBy Nasdaq OMXApr 23, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental NeurotherapeuticsBy Nasdaq OMXMar 12, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 7, 2018, 12:01 PM UTC
BusinessAxsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and DextromethorphanBy Nasdaq OMXFeb 26, 2018, 12:00 PM UTC
BusinessWave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System DisordersBy Nasdaq OMXFeb 20, 2018, 12:01 PM UTC
BusinessQ Therapeutics Announces Research Collaboration With REPROCELLBy Nasdaq OMXDec 13, 2017, 12:00 PM UTC
